A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Next Previous
Trial Profile

A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Spartalizumab (Primary) ; WNT 974 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Novartis

    • Most Recent Events

    • 22 Feb 2018 Planned End Date changed from 10 Jan 2020 to 9 Jan 2020.
    • 22 Feb 2018 Planned primary completion date changed from 25 Sep 2018 to 9 Jan 2020.
    • 24 Feb 2017 PDR-001 primary drug has been added hence treatment arms also increases from 1 to 2.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top